AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35648151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg BID)
Number of subjects: 2814
Study 35648151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 2814
Study 35648213 — intervention group
Group type: EXPERIMENTAL
Intervention: External Ventricular Device (EVD)
Number of subjects: 878
Study 35648213 — intervention group
Group type: COMPARATOR
Intervention: Intraparencymal monitor (IP)
Number of subjects: 878
Study 35648298 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss treatment
Number of subjects: 46
Study 35648298 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 46
Study 35648329 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine flow monitoring during cardiac surgery
Number of subjects: 0
Study 35648329 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 35648463 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-week core and pelvic health rehabilitation program starting 6 weeks postpartum and a 12-week resistance and high-intensity interval training program starting 12 weeks postpartum.
Number of subjects: 0
Study 35648463 — intervention group
Group type: COMPARATOR
Intervention: Standard care with no prescribed intervention.
Number of subjects: 0
Study 35648811 — intervention group
Group type: EXPERIMENTAL
Intervention: Efdamrofusp alfa (IBI302)
Number of subjects: 0
Study 35649117 — intervention group
Group type: EXPERIMENTAL
Intervention: LINAC-Based STAR
Number of subjects: 0
Study 35649178 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy
Number of subjects: 0
Study 35649202 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' feeding practices, specific practices not detailed, duration not specified.
Number of subjects: 0
Study 35649212 — intervention group
Group type: EXPERIMENTAL
Intervention: PER-HER
Number of subjects: 75
Study 35649212 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 35649282 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PUFA intake
Number of subjects: 109
Study 35649282 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake
Number of subjects: 109
Study 35649282 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 PUFA intake
Number of subjects: 109
Study 35649429 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 124
Study 35649479 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ultraradical lymph node debulking using Yasargil clamps
Number of subjects: 43
Study 35649600 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 940
Study 35649600 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccinated women
Number of subjects: 940
Study 35650179 — intervention group
Group type: EXPERIMENTAL
Intervention: RESTORE (Recovering from Extreme Stressors Through Online Resources and E-health)
Number of subjects: 21
Study 35650616 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cumulative fluid balance (median 1.98 L)
Number of subjects: 650
Study 35650616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cumulative fluid balance (median 0.78 L)
Number of subjects: 650
Study 35650616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cumulative fluid balance (median -0.35 L)
Number of subjects: 650
Study 35650617 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (PAP) intervention
Number of subjects: 60
Study 35651319 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera-based method for measuring vital signs (heart rate, blood oxygen saturation, respiratory rate, blood pressure)
Number of subjects: 214
Study 35651319 — intervention group
Group type: COMPARATOR
Intervention: Standard reference methods for measuring vital signs
Number of subjects: 214
Study 35651347 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT-ON sensor
Number of subjects: 84
Study 35651537 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 109
Study 35651624 — intervention group
Group type: EXPERIMENTAL
Intervention: ThyTreg obtained from pediatric thymus using a novel GMP protocol after a short-term culture of 7 days
Number of subjects: 0
Study 35651649 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation parameters in IBD patients
Number of subjects: 149
Study 35651649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired and inherited risk factors for thromboembolic events (TE)
Number of subjects: 149
Study 35651649 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical relevance of measuring coagulation parameters
Number of subjects: 149
Study 35651792 — intervention group
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cell therapy
Number of subjects: 1
Study 35651792 — intervention group
Group type: COMPARATOR
Intervention: Previous treatments (bortezomib, Adriamycin, dexamethasone, lenalidomide, daratumumab)
Number of subjects: 1
Study 35651818 — intervention group
Group type: EXPERIMENTAL
Intervention: Different sequenced pharmacotherapy options
Number of subjects: 0
Study 35651818 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (first-line pharmacotherapy)
Number of subjects: 0
Study 35651903 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (ICM)
Number of subjects: 100
Study 35652112 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg during the first CPR cycle and hydrocortisone 240 mg daily for 7 days maximum (steroids group)
Number of subjects: 184
Study 35652112 — intervention group
Group type: COMPARATOR
Intervention: Normal saline-placebo during the first CPR cycle and saline-placebo for postresuscitation shock (control group)
Number of subjects: 184
Study 35652190 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention to reduce delay from referral to admission, aiming for a benchmark period of 7 days.
Number of subjects: 0
Study 35652353 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging of the culprit lesion
Number of subjects: 1368
Study 35652524 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting heart rate
Number of subjects: 0
Study 35652820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (highest tertile)
Number of subjects: 2603
Study 35652820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfermented dairy intake (each 100-g increase)
Number of subjects: 2603
Study 35652820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (after excluding cheese intake)
Number of subjects: 2603
Study 35652820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy intake (after excluding those with elevated depressive symptoms at baseline)
Number of subjects: 2603
Study 35652820 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfermented dairy intake (highest tertile)
Number of subjects: 2603
Study 35652946 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL)
Number of subjects: 646
Study 35652960 — intervention group
Group type: EXPERIMENTAL
Intervention: TEM-ESD
Number of subjects: 145
Study 35653029 — intervention group
Group type: EXPERIMENTAL
Intervention: OC-01 VNS (0.06 mg)
Number of subjects: 18
Study 35653029 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 18
Study 35653046 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation following home-based HIV testing
Number of subjects: 37
Study 35653046 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV testing and referral for PrEP
Number of subjects: 37
Study 35653116 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 39
Study 35653122 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR-1701 at 30 mg/kg every 3 weeks
Number of subjects: 32
Study 35653138 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination as an adjuvant treatment
Number of subjects: 50
Study 35653138 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 50
Study 35653175 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Record app delivered on iPhones and Apple Watches, collecting continuous passive measures of physiological activation (heart rate) and physical activity (step count) over 30 days.
Number of subjects: 1019
Study 35653255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter monitoring in cardiogenic shock
Number of subjects: 0
Study 35653255 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial deformation imaging
Number of subjects: 0
Study 35653255 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic and extra-cardiac flow evaluation
Number of subjects: 0
Study 35653255 — intervention group
Group type: EXPERIMENTAL
Intervention: Various types of pulmonary artery catheters
Number of subjects: 0
Study 35653380 — intervention group
Group type: EXPERIMENTAL
Intervention: ETCO2 measurement; optimal cutoff value of 25.5 mmHg; sensitivity and specificity both 1.0 (AUC 1.0, p < 0.001) for predicting NGT tracheal misplacement.
Number of subjects: 85
Study 35653380 — intervention group
Group type: EXPERIMENTAL
Intervention: pH measurement; optimal cutoff value of 4.25; mild diagnostic accuracy (AUC 0.79, p < 0.001) for predicting NGT correct gastric placement.
Number of subjects: 85
Study 35653431 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with EA
Number of subjects: 21
Study 35653431 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 21
Study 35653438 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron BA.1 breakthrough infection
Number of subjects: 0
Study 35653440 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst Suppression Ratio (BSR)
Number of subjects: 90
Study 35653440 — intervention group
Group type: COMPARATOR
Intervention: Visual burst suppression detection in raw EEG
Number of subjects: 90
Study 35653440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative state entropy values >80
Number of subjects: 90
Study 35653552 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg monovalent HepB vaccine
Number of subjects: 205
Study 35653756 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa (AN)
Number of subjects: 0
Study 35653756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restraint, negative affect, and eating affect regulation expectancies
Number of subjects: 0
Study 35653756 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently low BMI
Number of subjects: 0
Study 35654563 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35654647 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 42
Study 35654732 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitinib 120 mg QD
Number of subjects: 72
Study 35654732 — intervention group
Group type: EXPERIMENTAL
Intervention: Epitinib 160 mg QD
Number of subjects: 72
Study 35655180 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft robotic exosuit-augmented high intensity gait training
Number of subjects: 5
Study 35655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral information
Number of subjects: 264
Study 35655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Referral information-Mental Health scale (cut-off value of 7)
Number of subjects: 264
Study 35655302 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral letter quality
Number of subjects: 264
Study 35655320 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF401 (120 mg qd)
Number of subjects: 74
Study 35655320 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF401 plus spartalizumab (FGF401 120 mg qd and spartalizumab 300 mg Q3W)
Number of subjects: 74
Study 35655320 — intervention group
Group type: COMPARATOR
Intervention: FGF401 (50 to 150 mg)
Number of subjects: 74
Study 35655320 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF401
Number of subjects: 74
Study 35655616 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 292
Study 35655837 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type III pedal arch
Number of subjects: 26
Study 35655837 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type I pedal arch
Number of subjects: 26
Study 35655837 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapopliteal intervention in patients with type II pedal arch
Number of subjects: 26
Study 35656394 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 78480
Study 35656394 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker treatment
Number of subjects: 78480
Study 35656720 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT: 1 anticoagulant and 2 antiplatelet agents)
Number of subjects: 514
Study 35656720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (1 anticoagulant + 1 antiplatelet agent)
Number of subjects: 514
Study 35656720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 514
Study 35656720 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT)
Number of subjects: 514
Study 35656931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist
Number of subjects: 6067
Study 35656931 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 6067
Study 35656931 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for treating AF
Number of subjects: 6067
Study 35656973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain physical rehabilitation intervention
Number of subjects: 0
Study 35656977 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of visit-to-visit systolic blood pressure (SBP) variability (SD)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of visit-to-visit SBP variability (SD)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of visit-to-visit SBP variability (SD)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 5-mm Hg increase in visit-to-visit SBP variability (SD)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of SBP variability (coefficient of variation)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of SBP variability (coefficient of variation)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile of SBP variability (variation independent of the mean)
Number of subjects: 1575
Study 35656977 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of SBP variability (variation independent of the mean)
Number of subjects: 1575
Study 35656982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pre-PCI pullback pressure gradient (PPG)
Number of subjects: 1685
Study 35656982 — intervention group
Group type: COMPARATOR
Intervention: High pre-PCI pullback pressure gradient (PPG)
Number of subjects: 1685
Study 35657008 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35657082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (weight loss)
Number of subjects: 139
Study 35657428 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-68-labeled fibroblast activation protein inhibitor PET
Number of subjects: 0
Study 35657429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
Number of subjects: 35
Study 35657429 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-functional disability at 12 months after CABM
Number of subjects: 281
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional disability at 12 months
Number of subjects: 281
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical disability at 12 months
Number of subjects: 281
Study 35657529 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone use
Number of subjects: 281
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal meningitis
Number of subjects: 281
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical disability at hospital discharge
Number of subjects: 281
Study 35657529 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral disorders at hospital discharge
Number of subjects: 281
Study 35657564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundled intervention including an electronic health record (EHR) portal-based conversation guide, EHR clinical decision support (CDS), and self-management educational materials.
Number of subjects: 32
Study 35657653 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06747775 monotherapy at recommended Phase 2 dose (200 mg QD)
Number of subjects: 65
Study 35657653 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06747775 200 mg QD plus palbociclib (100 mg QD orally)
Number of subjects: 65
Study 35657653 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06747775 monotherapy at RP2D in a Japanese lead-in cohort
Number of subjects: 65
Study 35657674 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 144
Study 35657674 — intervention group
Group type: COMPARATOR
Intervention: Online discussion forum (ODF)
Number of subjects: 144
Study 35657979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 306
Study 35657979 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+chemotherapy
Number of subjects: 306
Study 35657979 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 306
Study 35658005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adagrasib (600 mg orally twice daily)
Number of subjects: 116
Study 35658021 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of bullying in school
Number of subjects: 539
Study 35658021 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of belonging
Number of subjects: 539
Study 35658021 — intervention group
Group type: EXPERIMENTAL
Intervention: Being non-binary and being a transgender man
Number of subjects: 539
Study 35658021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to enter a STEM field
Number of subjects: 539
Study 35658021 — intervention group
Group type: COMPARATOR
Intervention: General sample comparison
Number of subjects: 539
Study 35658469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion after lymphodepletion
Number of subjects: 97
Study 35658518 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥25.0 kg/m²)
Number of subjects: 1227
Study 35658518 — intervention group
Group type: COMPARATOR
Intervention: Nonobese group (BMI <25.0 kg/m²)
Number of subjects: 1227
Study 35658525 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19 (2 × 10^6 cells/kg)
Number of subjects: 68
Study 35658525 — intervention group
Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 68
Study 35658861 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI trajectory from stable normal to overweight
Number of subjects: 138110
Study 35658861 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI trajectory from stable normal to obese
Number of subjects: 138110
Study 35658861 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI trajectory from overweight to obese
Number of subjects: 138110
Study 35658861 — intervention group
Group type: COMPARATOR
Intervention: Stable normal BMI
Number of subjects: 138110
Study 35658916 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal and domestic hygiene intervention including educational discussions and a brochure on lead exposure.
Number of subjects: 0
Study 35659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally competent care intervention
Number of subjects: 57
Study 35659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiated modifications by transplant team
Number of subjects: 57
Study 35659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual versus institutional modifications
Number of subjects: 57
Study 35659156 — intervention group
Group type: EXPERIMENTAL
Intervention: CFIR inner setting factors
Number of subjects: 57
Study 35659259 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home modular brain-computer interface (BCI) platform
Number of subjects: 1
Study 35659282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (TCZ) 7 mg/kg Q4W
Number of subjects: 24
Study 35659282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tocilizumab (TCZ) 6 mg/kg Q4W
Number of subjects: 24
Study 35659282 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tocilizumab (TCZ) 8 mg/kg Q4W (previous treatment)
Number of subjects: 24
Study 35659391 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid machine learning-based algorithm combining hierarchical agglomerative clustering analysis and permutation feature importance method.
Number of subjects: 0
Study 35659479 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs) and a PD-1 inhibitor
Number of subjects: 0
Study 35659581 — intervention group
Group type: EXPERIMENTAL
Intervention: Limertinib 160 mg orally twice daily
Number of subjects: 301
Study 35660135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 35660139 — intervention group
Group type: COMPARATOR
Intervention: Omicron phase (Dec 15, 2021, to Jan 31, 2022)
Number of subjects: 3473
Study 35660139 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients during omicron phase
Number of subjects: 3473
Study 35660542 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545
Study 35660542 — intervention group
Group type: COMPARATOR
Intervention: Cockcroft-Gault-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545
Study 35660542 — intervention group
Group type: COMPARATOR
Intervention: C-MDRD-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545
Study 35660542 — intervention group
Group type: COMPARATOR
Intervention: CKD-EPI-derived estimated glomerular filtration rate (eGFR)
Number of subjects: 61545